Europe's complacency problem

My latest guest on The Pharma Perspective, Neil Grubert, needs no introduction. When we talked about drug pricing, he told me the danger he sees is "a certain level of complacency in Europe": the belief that every important medicine reaches us sooner or later. We still count on it, even as MFN, the EU's new launch obligation, and the rise of the Chinese industry pull it apart.